Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70069 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Akihito Ogasawara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan. Hauptthemen laut MEDLINE: Receptor, Melanocortin, Type 1. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mitsubishi Tanabe Pharma Corporation.
Abstract (Originalsprache)
Dersimelagon is a novel investigational orally administered selective agonist of the melanocortin‐1 receptor. The drug–drug interaction (DDI) potential of dersimelagon was investigated in both nonclinical (in vitro) and clinical studies. The in vitro inhibition of CYP/UGT isoforms and efflux/uptake transporters by dersimelagon was assessed. The impact of 300‐mg dersimelagon on the pharmacokinetics (PK) of substrate drugs and the effect of co‐administering verapamil on 100‐mg dersimelagon PK (as substrate drug) were investigated in healthy participants in a Phase 1 study. DDIs were assessed based on ratios of C max and AUC 0‐∞ of substrate drug administered alone and with dersimelagon (or verapamil). Relatively potent in vitro inhibition of CYP2C9, CYP3A, UGT1A1, BCRP, P‐gp, and OATPs by dersimelagon was observed. In the clinical study, exposures of atorvastatin (CYP3A, P‐gp, BCRP, OATP substrate) rosuvastatin (BCRP and OATP substrate), and β ‐ hydroxy simvastatin (metabolite of simvastatin) increased 2‐ to 3‐fold (atorvastatin: C max LS mean ratio = 198.0%; AUC 0‐∞ ratio = 196.6%; rosuvastatin: C max ratio = 316.5%, AUC 0‐∞ ratio = 206.0%) when co‐administered with dersimelagon. Midazolam (CYP3A substrate), digoxin (P‐gp), pravastatin (OATP), and simvastatin (CYP3A) did not show any clinically relevant DDI effects when co‐administered with dersimelagon. Dersimelagon exposure increased ~25% when co‐administered with verapamil, an effect not considered clinically relevant. Dersimelagon 300 mg did not elicit major DDIs involving CYP/UGT enzymes and drug transporters; however, dersimelagon may have potential for clinically relevant DDIs with drugs that are substrates for BCRP, such as atorvastatin and rosuvastatin, and caution should be exercised when co‐administering 300‐mg dersimelagon with these statin drugs. Trial Registration: ClinicalTrials.gov : NCT04793295, NCT04402489, NCT04440592, NCT02834442, NCT03520036, NCT03503266
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
- CareCeutics LLC, Berwyn, Pennsylvania, USA.
ORCID-Profile: Akihito Ogasawara
Förderung
- Mitsubishi Tanabe Pharma Corporation
Zitieren
APA
Ogasawara, A., Ide, R., Inoue, S., Tsuda, M., & Teng, R. (2025). Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70069
Vancouver
Ogasawara A, Ide R, Inoue S, Tsuda M, Teng R. Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70069
BibTeX
@article{Ogasawara2025,
author = {Ogasawara, Akihito and Ide, Ryosuke and Inoue, Shinsuke and Tsuda, Minoru and Teng, Renli},
title = {Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70069}
}
EUVIMED